CHARLESTON, S.C. -- (Business Wire)
Aeterna Zentaris Inc. (NASDAQ & TSX: AEZS) a specialty
biopharmaceutical company (the “Company”) announced effective today,
September 25, 2017, that Jeffrey Whitnell has been appointed to the
position of Interim Chief Financial Officer. Whitnell is an accomplished
financial executive with a professional career spanning approximately 40
years in both large and small company environments working for various
organizations in the life sciences and biopharmaceutical sectors. Mr.
Whitnell brings extensive background in capital markets and corporate
finance transactions. Most recently, he served as Vice-President,
Finance & Controller of Lifewatch Services, Inc., a publicly traded
medical device company servicing the cardiac monitoring market that was
acquired by BioTelemetry, Inc. in July 2017. From April 2010 to March
2015, Mr. Whitnell served as Chief Financial Officer and Controller of
Reliefband Medical Technologies, a private equity-backed medical device
company, and from June 2004 to June 2009 Whitnell served as CFO of
Akorn, Inc., a then publicly traded specialty pharma company that was
recently acquired by Fresenius Kabi. Prior to that, Mr. Whitnell held
multiple senior finance positions with various companies, including
Ovation Pharmaceuticals, Medichem Life Sciences, Akzo Nobel and
Motorola. He commenced his professional career as a staff auditor with
Arthur Andersen & Co. Mr. Whitnell has a Bachelor’s of Science degree in
Accountancy from the University of Illinois and a Master’s in Business
Administration from The University of Chicago Booth School of Business.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company engaged in
developing and commercializing novel pharmaceutical therapies. We are
engaged in drug development activities and in the promotion of products
for others. We recently resubmitted an NDA to the FDA seeking approval
of MacrilenTM, an internally developed compound. The focus of
our business development efforts is the acquisition of licenses to
products that are relevant to our therapeutic areas of focus. We also
intend to license out certain commercial rights of internally developed
products to licensees in non-U.S. territories where such out-licensing
would enable us to ensure development, registration and launch of our
product candidates. Our goal is to become a growth-oriented specialty
biopharmaceutical company by pursuing successful development and
commercialization of our product portfolio, achieving successful
commercial presence and growth, while consistently delivering value to
our shareholders, employees and the medical providers and patients who
will benefit from our products. For more information, visit www.aezsinc.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170925006423/en/
Contacts:
Aeterna Zentaris Inc.
Michael V. Ward
Chief Executive Officer
IR@aezsinc.com
843.900.3223
or
Reilly
Connect
Susan Reilly
susan.reilly@reillyconnect.com
312.600.6783
Source: Aeterna Zentaris Inc.
© 2024 Canjex Publishing Ltd. All rights reserved.